Fusion Tyrosine Kinases Induce Drug Resistance by Stimulation of Homology-Dependent Recombination Repair, Prolongation of G₂/M Phase, and Protection from Apoptosis

REFERENCES

• Amarante-Mendes, G. P., A. J. McGahon, W. K. Nishioka, D. E. Afar, O. N. Witte, and D. R. Green. 1998. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL. Oncogene 16: 1383–1390.
   PubMed Web of Science ®Google Scholar
• Amarante-Mendes, G. P., C. Naekyung Kim, L. Liu, Y. Huang, C. L. Perkins, D. R. Green, and K. Bhalla. 1998. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood 91: 1700–1705.
   PubMed Web of Science ®Google Scholar
• Arnaudeau, C., C. Lundin, and T. Helleday. 2001. DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. J. Mol. Biol. 307: 1235–1245.
   PubMed Web of Science ®Google Scholar
• Bedi, A., J. P. Barber, G. C. Bedi, W. S. el-Deiry, D. Sidransky, M. S. Vala, A. J. Akhtar, J. Hilton, and R. J. Jones. 1995. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood 86: 1148–1158.
   PubMed Web of Science ®Google Scholar
• Bishop, A. J., and R. H. Schiestl. 2001. Homologous recombination as a mechanism of carcinogenesis. Biochim. Biophys. Acta 1471: M109–121.
   PubMed Web of Science ®Google Scholar
• Blume-Jensen, P., and T. Hunter. 2001. Oncogenic kinase signalling. Nature 411: 355–365.
   PubMed Web of Science ®Google Scholar
• Bucka, A., and A. Stasiak. 2001. RecA-mediated strand exchange traverses substitutional heterologies more easily than deletions or insertions. Nucleic Acids Res. 29: 2464–2470.
   PubMedGoogle Scholar
• Chan, T. A., H. Hermeking, C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1999. 14-3-3sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616–620.
   PubMed Web of Science ®Google Scholar
• Chan, T. A., P. M. Hwang, H. Hermeking, K. W. Kinzler, and B. Vogelstein. 2000. Cooperative effects of genes controlling the G2/M checkpoint. Genes Dev. 14: 1584–1588.
   PubMed Web of Science ®Google Scholar
• Christodoulopoulos, G., A. Malapetsa, H. Schipper, E. Golub, C. Radding, and L. C. Panasci. 1999. Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia. Clin. Cancer Res. 5: 2178–2184.
   PubMed Web of Science ®Google Scholar
• Clark, S. S., J. McLaughlin, M. Timmons, A. M. Pendergast, Y. Ben-Neriah, L. W. Dow, W. Crist, G. Rovera, S. D. Smith, and O. N. Witte. 1988. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 239: 775–777.
   PubMed Web of Science ®Google Scholar
• Collins, M. K., J. Marvel, P. Malde, and A. Lopez-Rivas. 1992. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J. Exp. Med. 176: 1043–1051.
   PubMed Web of Science ®Google Scholar
• Collis, S. J., A. Tighe, S. D. Scott, S. A. Roberts, J. H. Hendry, and G. P. Margison. 2001. Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. Nucleic Acids Res. 29: 1534–1538.
   PubMed Web of Science ®Google Scholar
• Dasika, G. K., S. C. Lin, S. Zhao, P. Sung, A. Tomkinson, and E. Y. Lee. 1999. DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. Oncogene 18: 7883–7899.
   PubMed Web of Science ®Google Scholar
• Deutsch, E., A. Dugray, B. AbdulKarim, E. Marangoni, L. Maggiorella, S. Vaganay, R. M'Kacher, S. D. Rasy, F. Eschwege, W. Vainchenker, A. G. Turhan, and J. Bourhis. 2001. BCR-ABL down-regulates the DNA repair protein DNA-PKcs. Blood 97: 2084–2090.
   PubMed Web of Science ®Google Scholar
• Druker, B. J., S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning, J. Zimmermann, and N. B. Lydon. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561–566.
   PubMed Web of Science ®Google Scholar
• Dubrez, L., B. Eymin, O. Sordet, N. Droin, A. G. Turhan, and E. Solary. 1998. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 91: 2415–2422.
   PubMed Web of Science ®Google Scholar
• el-Deiry, W. S. 1997. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol. 9: 79–87.
   PubMedGoogle Scholar
• Epner, D. E., and H. P. Koeffler. 1990. Molecular genetic advances in chronic myelogenous leukemia. Ann. Intern. Med. 113: 3–6.
   PubMed Web of Science ®Google Scholar
• Fukushima, T., M. Takata, C. Morrison, R. Araki, A. Fujimori, M. Abe, K. Tatsumi, M. Jasin, P. K. Dhar, E. Sonoda, T. Chiba, and S. Takeda. 2001. Genetic analysis of the DNA-dependent protein kinase reveals an inhibitory role of Ku in late S-G2 phase DNA double-strand break repair. J. Biol. Chem. 276: 44413–44418.
   PubMedGoogle Scholar
• Gesbert, F., W. R. Sellers, S. Signoretti, M. Loda, and J. D. Griffin. 2000. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J. Biol. Chem. 275: 39223–39230.
   PubMed Web of Science ®Google Scholar
• Goldie, J. H. 1994. Modelling the process of drug resistance. Lung Cancer 10: S91–S96.
   PubMedGoogle Scholar
• Golub, T. R., G. F. Barker, M. Lovett, and D. G. Gilliland. 1994. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77: 307–316.
   PubMed Web of Science ®Google Scholar
• Golub, T. R., A. Goga, G. F. Barker, D. E. Afar, J. McLaughlin, S. K. Bohlander, J. D. Rowley, O. N. Witte, and D. G. Gilliland. 1996. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol. Cell. Biol. 16: 4107–4116.
   PubMed Web of Science ®Google Scholar
• Greenland, C., C. Touriol, G. Chevillard, S. W. Morris, R. Bai, J. Duyster, G. Delsol, and M. Allouche. 2001. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis. Oncogene 20: 7386–7397.
   PubMed Web of Science ®Google Scholar
• Gross, A., J. M. McDonnell, and S. J. Korsmeyer. 1999. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13: 1899–1911.
   PubMed Web of Science ®Google Scholar
• Hampson, R. 1997. Selection for genome instability by DNA damage in human cells: unstable microsatellites and their consequences for tumourigenesis. Radiat. Oncol. Investig. 5: 111–114.
   PubMedGoogle Scholar
• Harrison, D. J. 1995. Molecular mechanisms of drug resistance in tumours. J. Pathol. 175: 7–12.
   PubMed Web of Science ®Google Scholar
• Hoover, R. R., M. J. Gerlach, E. Y. Koh, and G. Q. Daley. 2001. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene 20: 5826–5835.
   PubMedGoogle Scholar
• Horita, M., E. J. Andreu, A. Benito, C. Arbona, C. Sanz, I. Benet, F. Prosper, and J. L. Fernandez-Luna. 2000. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J. Exp. Med. 191: 977–984.
   PubMed Web of Science ®Google Scholar
• Johnson, B. W., E. Cepero, and L. H. Boise. 2000. Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha. J. Biol. Chem. 275: 31546–31553.
   PubMedGoogle Scholar
• Johnson, P. A., P. Clements, K. Hudson, and K. W. Caldecott. 1999. A mitotic spindle requirement for DNA damage-induced apoptosis in Chinese hamster ovary cells. Cancer Res. 59: 2696–2700.
   PubMed Web of Science ®Google Scholar
• Karni, R., R. Jove, and A. Levitzki. 1999. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18: 4654–4662.
   PubMed Web of Science ®Google Scholar
• Khanna, K. K., and S. P. Jackson. 2001. DNA double-strand breaks: signaling, repair and the cancer connection. Nat. Genet. 27: 247–254.
   PubMed Web of Science ®Google Scholar
• Kolibaba, K. S., and B. J. Druker. 1997. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta 1333: F217–F248.
   PubMed Web of Science ®Google Scholar
• Kolomietz, E., J. Al-Maghrabi, S. Brennan, J. Karaskova, S. Minkin, J. Lipton, and J. A. Squire. 2001. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97: 3581–3588.
   PubMed Web of Science ®Google Scholar
• Lacronique, V., A. Boureux, V. D. Valle, H. Poirel, C. T. Quang, M. Mauchauffe, C. Berthou, M. Lessard, R. Berger, J. Ghysdael, and O. A. Bernard. 1997. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278: 1309–1312.
   PubMed Web of Science ®Google Scholar
• Ladanyi, M. 2000. Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms. Am. J. Pathol. 157: 341–345.
   PubMed Web of Science ®Google Scholar
• Li, X., and M. Cai. 1997. Inactivation of the cyclin-dependent kinase Cdc28 abrogates cell cycle arrest induced by DNA damage and disassembly of mitotic spindles in Saccharomyces cerevisiae. Mol. Cell. Biol. 17: 2723–2734.
   PubMed Web of Science ®Google Scholar
• Lim, D.-S., and P. Hasty. 1996. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol. Cell. Biol. 16: 7133–7143.
   PubMed Web of Science ®Google Scholar
• Liu, Q., J. Schwaller, J. Kutok, D. Cain, J. C. Aster, I. R. Williams, and D. G. Gilliland. 2000. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15) (p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J. 19: 1827–1838.
   PubMed Web of Science ®Google Scholar
• Maacke, H., K. Jost, S. Opitz, S. Miska, Y. Yuan, L. Hasselbach, J. Luttges, H. Kalthoff, and H. W. Sturzbecher. 2000. DNA repair and recombination factor rad51 is overexpressed in human pancreatic adenocarcinoma. Oncogene 19: 2791–2795.
   PubMed Web of Science ®Google Scholar
• Masumoto, N., S. Nakano, H. Fujishima, K. Kohno, and Y. Niho. 1999. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int. J. Cancer 80: 731–737.
   PubMed Web of Science ®Google Scholar
• Morris, S. W., M. N. Kirstein, M. B. Valentine, K. Dittmer, D. N. Shapiro, A. T. Look, and D. L. Saltman. 1995. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 267: 316–317.
   PubMed Web of Science ®Google Scholar
• Nieborowska-Skorska, M., M. A. Wasik, A. Slupianek, P. Salomoni, T. Kitamura, B. Calabretta, and T. Skorski. 1999. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 189: 1229–1242.
   PubMed Web of Science ®Google Scholar
• Nishii, K., J. H. Kabarowski, D. L. Gibbons, S. D. Griffiths, I. Titley, L. M. Wiedemann, and M. F. Greaves. 1996. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene 13: 2225–2234.
   PubMed Web of Science ®Google Scholar
• Norbury, C. J., and I. D. Hickson. 2001. Cellular responses to DNA damage. Annu. Rev. Pharmacol. Toxicol. 41: 367–401.
   PubMed Web of Science ®Google Scholar
• Oetzel, C., T. Jonuleit, A. Gotz, H. van der Kuip, H. Michels, J. Duyster, M. Hallek, and W. E. Aulitzky. 2000. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin. Cancer Res. 6: 1958–1968.
   PubMed Web of Science ®Google Scholar
• Ohnishi, T., T. Taki, S. Hiraga, N. Arita, and T. Morita. 1998. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem. Biophys. Res. Commun. 245: 319–324.
   PubMed Web of Science ®Google Scholar
• Pear, W. S., J. P. Miller, L. Xu, J. C. Pui, B. Soffer, R. C. Quackenbush, A. M. Pendergast, R. Bronson, J. C. Aster, M. L. Scott, and D. Baltimore. 1998. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92: 3780–3792.
   PubMed Web of Science ®Google Scholar
• Peeters, P., S. D. Raynaud, J. Cools, I. Wlodarska, J. Grosgeorge, P. Philip, F. Monpoux, L. Van Rompaey, M. Baens, H. Van den Berghe, and P. Marynen. 1997. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood 90: 2535–2540.
   PubMed Web of Science ®Google Scholar
• Pierce, A. J., R. D. Johnson, L. H. Thompson, and M. Jasin. 1999. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13: 2633–2638.
   PubMed Web of Science ®Google Scholar
• Pietras, R. J., B. M. Fendly, V. R. Chazin, M. D. Pegram, S. B. Howell, and D. J. Slamon. 1994. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9: 1829–1838.
   PubMed Web of Science ®Google Scholar
• Raitano, A. B., Y. E. Whang, and C. L. Sawyers. 1997. Signal transduction by wild-type and leukemogenic Abl proteins. Biochim. Biophys. Acta 1333: F201–F216.
   PubMed Web of Science ®Google Scholar
• Reed, J. C. 1997. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin. Hematol. 34: 9–19.
   PubMed Web of Science ®Google Scholar
• Rieder, C. L., and R. Cole. 2000. Microtubule disassembly delays the G2-M transition in vertebrates. Curr. Biol. 10: 1067–1070.
   PubMedGoogle Scholar
• Rieder, C. L., and R. W. Cole. 1998. Entry into mitosis in vertebrate somatic cells is guarded by a chromosome damage checkpoint that reverses the cell cycle when triggered during early but not late prophase. J. Cell Biol. 142: 1013–1022.
   PubMed Web of Science ®Google Scholar
• Saintigny, Y., A. Dumay, S. Lambert, and B. S. Lopez. 2001. A novel role for the Bcl-2 protein family: specific suppression of the RAD51 recombination pathway. EMBO J. 20: 2596–2607.
   PubMed Web of Science ®Google Scholar
• Salomoni, P., F. Condorelli, S. M. Sweeney, and B. Calabretta. 2000. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 96: 676–684.
   PubMed Web of Science ®Google Scholar
• Sanchez-Garcia, I., and D. Martin-Zanca. 1997. Regulation of Bcl-2 gene expression by BCR-ABL is mediated by Ras. J. Mol. Biol. 267: 225–228.
   PubMed Web of Science ®Google Scholar
• Sattler, M., and R. Salgia. 1997. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev. 8: 63–79.
   PubMedGoogle Scholar
• Shah, J. V., and D. W. Cleveland. 2000. Waiting for anaphase: Mad2 and the spindle assembly checkpoint. Cell 103: 997–1000.
   PubMed Web of Science ®Google Scholar
• Shinohara, A., and T. Ogawa. 1995. Homologous recombination and the roles of double-strand breaks. Trends Biochem. Sci. 20: 387–391.
   PubMed Web of Science ®Google Scholar
• Shtivelman, E., B. Lifshitz, R. P. Gale, B. A. Roe, and E. Canaani. 1986. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell 47: 277–284.
   PubMed Web of Science ®Google Scholar
• Sillaber, C., F. Gesbert, D. A. Frank, M. Sattler, and J. D. Griffin. 2000. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95: 2118–2125.
   PubMed Web of Science ®Google Scholar
• Singh, N. P., M. T. McCoy, R. R. Tice, and E. L. Schneider. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175: 184–191.
   PubMed Web of Science ®Google Scholar
• Skorski, T., A. Bellacosa, M. Nieborowska-Skorska, M. Majewski, R. Martinez, J. K. Choi, R. Trotta, P. Wlodarski, D. Perrotti, T. O. Chan, M. A. Wasik, P. N. Tsichlis, and B. Calabretta. 1997. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J. 16: 6151–6161.
   PubMed Web of Science ®Google Scholar
• Skorski, T., P. Kanakaraj, D. H. Ku, M. Nieborowska-Skorska, E. Canaani, G. Zon, B. Perussia, and B. Calabretta. 1994. Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth. J. Exp. Med. 179: 1855–1865.
   PubMed Web of Science ®Google Scholar
• Skorski, T., P. Kanakaraj, M. Nieborowska-Skorska, M. Z. Ratajczak, S. C. Wen, G. Zon, A. M. Gewirtz, B. Perussia, and B. Calabretta. 1995. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86: 726–736.
   PubMed Web of Science ®Google Scholar
• Skorski, T., M. Nieborowska-Skorska, K. Campbell, R. V. Iozzo, G. Zon, Z. Darzynkiewicz, and B. Calabretta. 1995. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J. Exp. Med. 182: 1645–1653.
   PubMed Web of Science ®Google Scholar
• Skorski, T., M. Nieborowska-Skorska, P. Wlodarski, D. Perrotti, R. Martinez, M. A. Wasik, and B. Calabretta. 1996. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc. Natl. Acad. Sci. USA 93: 13137–13142.
   PubMed Web of Science ®Google Scholar
• Slupianek, A., M. Nieborowska-Skorska, G. Hoser, A. Morrione, M. Majewski, L. Xue, S. W. Morris, M. A. Wasik, and T. Skorski. 2001. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res. 61: 2194–2199.
   PubMed Web of Science ®Google Scholar
• Slupianek, A., C. Schmutte, G. Tombline, M. Nieborowska-Skorska, G. Hoser, M. O. Nowicki, A. J. Pierce, R. Fishel, and T. Skorski. 2001. BCR/ABL regulates mammalian recA homologs, resulting in drug resistance. Mol. Cell 8: 795–806.
   PubMed Web of Science ®Google Scholar
• Socolovsky, M., A. E. Fallon, S. Wang, C. Brugnara, and H. F. Lodish. 1999. Fetal anemia and apoptosis of red cell progenitors in Stat5a−/− 5b−/− mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 98: 181–191.
   PubMed Web of Science ®Google Scholar
• Sonoda, E., M. S. Sasaki, J. M. Buerstedde, O. Bezzubova, A. Shinohara, H. Ogawa, M. Takata, Y. Yamaguchiiwai, and S. Takeda. 1998. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J. 17: 598–608.
   PubMed Web of Science ®Google Scholar
• Sonoda, E., M. S. Sasaki, C. Morrison, Y. Yamaguchi-Iwai, M. Takata, and S. Takeda. 1999. Sister chromatid exchanges are mediated by homologous recombination in vertebrate cells. Mol. Cell. Biol. 19: 5166–5169.
   PubMed Web of Science ®Google Scholar
• Stiewe, T., K. Parssanedjad, H. Esche, B. Opalka, and B. M. Putzer. 2000. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents. Cancer Res. 60: 3957–3964.
   PubMedGoogle Scholar
• Tsuzuki, T., Y. Fujii, K. Sakumi, Y. Tominaga, K. Nakao, M. Sekiguchi, A. Matsushiro, Y. Yoshimura, and T. Morita. 1996. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc. Natl. Acad. Sci. USA 93: 6236–6240.
   PubMed Web of Science ®Google Scholar
• Vispe, S., C. Cazaux, C. Lesca, and M. Defais. 1998. Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. Nucleic Acids Res. 26: 2859–2864.
   PubMed Web of Science ®Google Scholar
• Wang, Y., and D. J. Burke. 1995. Checkpoint genes required to delay cell division in response to nocodazole respond to impaired kinetochore function in the yeast Saccharomyces cerevisiae. Mol. Cell. Biol. 15: 6838–6844.
   PubMedGoogle Scholar
• Xia, S. J., M. A. Shammas, and R. J. S. Reis. 1997. Elevated recombination in immortal human cells is mediated by HsRAD51 recombinase. Mol. Cell. Biol. 17: 7151–7158.
   PubMed Web of Science ®Google Scholar
• Zdraveski, Z. Z., J. A. Mello, M. G. Marinus, and J. M. Essigmann. 2000. Multiple pathways of recombination define cellular responses to cisplatin. Chem. Biol. 7: 39–50.
   PubMed Web of Science ®Google Scholar
• Zhai, Y., P. J. Kronebusch, P. M. Simon, and G. G. Borisy. 1996. Microtubule dynamics at the G2/M transition: abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis. J. Cell Biol. 135: 201–214.
   PubMedGoogle Scholar
• Zhou, B. B., P. Chaturvedi, K. Spring, S. P. Scott, R. A. Johanson, R. Mishra, M. R. Mattern, J. D. Winkler, and K. K. Khanna. 2000. Caffeine abolishes the mammalian G2/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J. Biol. Chem. 275: 10342–10348.
   PubMed Web of Science ®Google Scholar
• Zou, X., and K. Calame. 1999. Signaling pathways activated by oncogenic forms of Abl tyrosine kinase. J. Biol. Chem. 274: 18141–18144.
   PubMed Web of Science ®Google Scholar